NASDAQ:HCWB - Nasdaq - US40423R1059 - Common Stock - Currency: USD
0.3387
-0.02 (-5.05%)
The current stock price of HCWB is 0.3387 USD. In the past month the price decreased by -37.74%. In the past year, price decreased by -79.72%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.9 | 373.82B | ||
AMGN | AMGEN INC | 15.97 | 170.00B | ||
GILD | GILEAD SCIENCES INC | 25.04 | 143.84B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1695.31 | 126.30B | ||
REGN | REGENERON PHARMACEUTICALS | 15.06 | 75.12B | ||
ARGX | ARGENX SE - ADR | 247.66 | 38.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.15B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.98B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.51B | ||
BIIB | BIOGEN INC | 8.73 | 20.95B | ||
NTRA | NATERA INC | N/A | 19.53B | ||
GMAB | GENMAB A/S -SP ADR | 25.37 | 15.31B |
HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The company is headquartered in Miramar, Florida and currently employs 45 full-time employees. The company went IPO on 2021-07-20. The company is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. The company has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
HCW BIOLOGICS INC
2929 N Commerce Pkwy, Miramar, Fl 33025
Miramar FLORIDA US
Employees: 45
Company Website: https://hcwbiologics.com/
Investor Relations: https://investors.hcwbiologics.com/
Phone: 19548422024
The current stock price of HCWB is 0.3387 USD. The price decreased by -5.05% in the last trading session.
The exchange symbol of HCW BIOLOGICS INC is HCWB and it is listed on the Nasdaq exchange.
HCWB stock is listed on the Nasdaq exchange.
7 analysts have analysed HCWB and the average price target is 3.06 USD. This implies a price increase of 803.45% is expected in the next year compared to the current price of 0.3387. Check the HCW BIOLOGICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
HCW BIOLOGICS INC (HCWB) has a market capitalization of 15.09M USD. This makes HCWB a Nano Cap stock.
HCW BIOLOGICS INC (HCWB) currently has 45 employees.
HCW BIOLOGICS INC (HCWB) has a resistance level at 0.38. Check the full technical report for a detailed analysis of HCWB support and resistance levels.
The Revenue of HCW BIOLOGICS INC (HCWB) is expected to grow by 368.22% in the next year. Check the estimates tab for more information on the HCWB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HCWB does not pay a dividend.
HCW BIOLOGICS INC (HCWB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).
The outstanding short interest for HCW BIOLOGICS INC (HCWB) is 3.4% of its float. Check the ownership tab for more information on the HCWB short interest.
ChartMill assigns a fundamental rating of 1 / 10 to HCWB. HCWB has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months HCWB reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -66.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -140.57% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to HCWB. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 16.94% and a revenue growth 368.22% for HCWB